Originally published February 18, 2009 at 12:00 AM | Page modified February 18, 2009 at 1:37 PM
PrintCell Therapeutics stock resumes trading after week-long halt
By Seattle Times business staff
After a week-long suspension, shares of Cell Therapeutics resumed trading Wednesday on Nasdaq and the Borsa Italiana in Milan.
Trading was halted by the Milan exchange Feb. 10 as Italian securities regulators pressed the cash-strapped Seattle biotechnology company for detailed financial information not contained in its U.S. securities filings. Nasdaq stopped U.S. trading in reaction to the Italian move.
Cell Therapeutics said late Tuesday that the Borsa Italiana had confirmed it was lifting the trading halt after the company submitted additional information on its business operations and financial condition.
The company's stock is traded in Italy because it has a large number of stockholders there following its 2003 acquisition of Novuspharma, a Milan-based biotech company. It is now trying to sell its Italian operations.
Before the trading halt, Cell Therapeutics shares last traded at 8 cents, with a 52-week range of $16.70 to 5 cents. The stock closed today at 6.9 cents, down 1.5 cents, or 18 percent, on Nasdaq.
The 16-year-old company has an accumulated deficit of more than $1 billion and in recent months has issued vast quantities of new stock as it restructures its debt.
Copyright © 2009 The Seattle Times Company
Print
Digg
Newsvine
Rescue of 13-year-old boy at Wallace Falls
Museum officials discuss King Tut exhibit installation
Kayak surfing
Male song birds
Newly hired Seattle schools superintendent Jose Banda
Inmates work with abandoned felines
May Day raw video: Protesters march along Jackson
May Day raw video: Rally at Marion St. and 2nd Ave
May Day raw video: Police attempt to clear downtown intersection
Open Houses
|
Find all open houses.
|
nwautos
(Daihatsu) Daihatsu FC Sho Case This futuristic four-seater debuted at the Tokyo auto show in December. Its seats can fold flat into the floor and th...
Post a comment
- Madrona dad killed by a bullet as he drove through Central Area
- SPU surprises neighbors with sale of Queen Anne rec property
- Beer-drinking bridge builders will get training from a counselor
- Matt Flynn has good day in Seahawks' 3-way QB competition
- Boy's pat on president's head captured for history
- Why dealing for Kellen Winslow makes sense for Seahawks | Steve Kelley
- Police arrest New Jersey man who confessed to killing Etan Patz
- Amazon addresses criticism at meeting
- Driver fatally shot in Central Area
- Facebook messages trigger melee at Whitman Middle School
- Opponents of gay-marriage law say they have enough signatures
860 - Mariners look to get back on winning track against Angels 472
- Madrona dad killed by stray bullet as he drove through Central Area 259
- Komen controversy hurting Race for the Cure 216
- Typical CEO made $9.6M last year, AP study finds 148
- Sources: DOJ sends letters to city blasting police reform efforts 138
- Fact check: Ad exaggerates Obama's debt 96
- Driver caught in crossfire, fatally shot in Central Area 89
- It's been great; see you soon in my new columns 71
- Eric Wedge not happy with Mariners after 14-strikeout perfromance versus Dan Haren 60
- Madrona dad killed by a bullet as he drove through Central Area
- Dig into colorful history at Oregon's John Day Fossil Beds
- Get a sitter — please — for these 10 great date-night restaurants | All You Can Eat
- SPU surprises neighbors with sale of Queen Anne rec property
- Beer-drinking bridge builders will get training from a counselor
- Zumiez rebounds from recession better than most
- Boy's pat on president's head captured for history
- Driver fatally shot in Central Area
- Downtown building fetches $55M, thanks to Amazon effect
- Gates Foundation grants give local groups a boost
